US 12,280,159 B2
Therapeutic protein-based nanoparticles for treating cancer
Joerg Lahann, Ann Arbor, MI (US); Nahal Habibi, Ann Arbor, MI (US); Jason V. Gregory, Ann Abor, MI (US); Maria Castro, Ann Arbor, MI (US); Pedro Lowenstein, Ann Arbor, MI (US); Ava Mauser, Corrales, NM (US); Padma Kadiyala, Ann Arbor, MI (US); Daniel F. Quevedo, Lexington, VA (US); and Felipe Nunez, Ann Arbor, MI (US)
Assigned to The Regents of The University of Michigan, Ann Arbor, MI (US)
Filed by THE REGENTS OF THE UNIVERSITY OF MICHIGAN, Ann Arbor, MI (US)
Filed on Nov. 8, 2021, as Appl. No. 17/521,414.
Claims priority of provisional application 63/120,589, filed on Dec. 2, 2020.
Claims priority of provisional application 63/112,086, filed on Nov. 10, 2020.
Claims priority of provisional application 63/110,828, filed on Nov. 6, 2020.
Prior Publication US 2022/0142936 A1, May 12, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. B82Y 5/00 (2011.01); A61K 9/51 (2006.01); A61K 31/7105 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); B82Y 40/00 (2011.01)
CPC A61K 9/5169 (2013.01) [A61K 9/5192 (2013.01); A61K 31/7105 (2013.01); A61P 35/00 (2018.01); A61K 9/0085 (2013.01); B82Y 5/00 (2013.01); B82Y 40/00 (2013.01)] 25 Claims
 
1. A nanoparticle comprising an inhibitor of a transcription factor and a cross-linked water-soluble protein having a mesh structure encapsulating the inhibitor of the transcription factor, wherein the water-soluble protein has an average molecular weight of greater than or equal to about 8 kDa and less than or equal to about 700 kDa and the water-soluble protein has a predominantly native conformation due to the absence of alcohols or acetone during formation of the mesh structure.